UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023

Rhea-AI Summary

UroGen Pharma Ltd. (NASDAQ: URGN) will report its fourth quarter and full-year 2022 financial results on March 16, 2023, before the stock market opens. A conference call will follow at 10:00 AM ET, accessible via a live webcast on UroGen’s Investor Relations website. The company is focused on innovative treatments for urothelial and specialty cancers, featuring its proprietary RTGel™ hydrogel technology and products like Jelmyto® for non-surgical tumor ablation. UroGen aims to improve therapeutic options for patients through sustained release mechanisms.

Positive

• Potential growth through proprietary RTGel™ hydrogel technology.
• First commercial product Jelmyto® addresses unmet medical needs.
• Focus on innovative cancer treatments could enhance market position.

Negative

• None.

Conference Call and Webcast Scheduled for Thursday, March 16, 2023, at 10:00 AM ET

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2022 financial results on Thursday, March 16, 2023, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005742/en/

INVESTORS:

Vincent Perrone

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma report its earnings results for Q4 2022?

UroGen Pharma will report its fourth quarter and full-year 2022 financial results on March 16, 2023.

What time is the UroGen Pharma earnings conference call?

The earnings conference call is scheduled for 10:00 AM ET on March 16, 2023.

How can I access the UroGen Pharma earnings conference call?

The conference call can be accessed via a live webcast on UroGen’s Investor Relations website.

What innovative technologies does UroGen Pharma use in its treatments?

UroGen Pharma utilizes its proprietary RTGel™ hydrogel technology to enhance treatment options for urothelial and specialty cancers.

What is UroGen's first commercial product?

UroGen's first commercial product is Jelmyto® for the treatment of tumors as a non-surgical option.